Aprecia, the 3DP Pharmaceutical Company, has named Kathi Rinesmith, R Ph, MS as its new Senior Vice President of Regulatory Affairs, it was reported on Wednesday.

Rinesmith will head the firm's regulatory strategy, objectives, policies, and programmes for the development and marketing of drug products manufactured with ZipDose Technology, the company's three-dimensional printing technology platform.

Rinesmith has over thirty years of pharmaceutical experience. Most recently, Rinesmith held the position of Director of Global Regulatory Affairs and Global Pharmacovigilance at Adare Pharmaceuticals. He has regulatory and pharmacovigilance experience in commercialised Rx, OTC, and dietary supplement products, and has served as senior executive product development and regulatory roles at Camargo Pharmaceutical Services, Prasco Laboratories, Barr Labs, and Duramed Pharmaceuticals.